Literature DB >> 24702509

Characterization of intratumor magnetic nanoparticle distribution and heating in a rat model of metastatic spine disease.

Patricia L Zadnik1, Camilo A Molina, Rachel Sarabia-Estrada, Mari L Groves, Michele Wabler, Jana Mihalic, Edward F McCarthy, Ziya L Gokaslan, Robert Ivkov, Daniel Sciubba.   

Abstract

OBJECT: The goal of this study was to optimize local delivery of magnetic nanoparticles in a rat model of metastatic breast cancer in the spine for tumor hyperthermia while minimizing systemic exposure.
METHODS: A syngeneic mammary adenocarcinoma was implanted into the L-6 vertebral body of 69 female Fischer rats. Suspensions of 100-nm starch-coated iron oxide magnetic nanoparticles (micromod Partikeltechnologie GmbH) were injected into tumors 9 or 13 days after implantation. For nanoparticle distribution studies, tissues were harvested from a cohort of 36 rats, and inductively coupled plasma mass spectrometry and histopathological studies with Prussian blue staining were used to analyze the samples. Intratumor heating was tested in 4 anesthetized animals with a 20-minute exposure to an alternating magnetic field (AMF) at a frequency of 150 kHz and an amplitude of 48 kA/m or 63.3 kA/m. Intratumor and rectal temperatures were measured, and functional assessments of AMF-exposed animals and histopathological studies of heated tumor samples were examined. Rectal temperatures alone were tested in a cohort of 29 rats during AMF exposure with or without nanoparticle administration. Animal studies were completed in accordance with the protocols of the University Animal Care and Use Committee.
RESULTS: Nanoparticles remained within the tumor mass within 3 hours of injection and migrated into the bone at 6, 12, and 24 hours. Subarachnoid accumulation of nanoparticles was noted at 48 hours. No evidence of lymphoreticular nanoparticle exposure was found on histological investigation or via inductively coupled plasma mass spectrometry. The mean intratumor temperatures were 43.2°C and 40.6°C on exposure to 63.3 kA/m and 48 kA/m, respectively, with histological evidence of necrosis. All animals were ambulatory at 24 hours after treatment with no evidence of neurological dysfunction.
CONCLUSIONS: Locally delivered magnetic nanoparticles activated by an AMF can generate hyperthermia in spinal tumors without accumulating in the lymphoreticular system and without damaging the spinal cord, thereby limiting neurological dysfunction and minimizing systemic exposure. Magnetic nanoparticle hyperthermia may be a viable option for palliative therapy of spinal tumors.

Entities:  

Keywords:  AMF = alternating magnetic field; BNF = Bionized Nanoferrite; ICP-MS = inductively coupled plasma mass spectrometry; PB = Prussian blue; SLP = specific loss power; VB = vertebral body; hyperthermia; iron oxide nanoparticles; magnetic nanoparticles; oncology; rat; spine; tumor

Mesh:

Substances:

Year:  2014        PMID: 24702509     DOI: 10.3171/2014.2.SPINE13142

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  8 in total

1.  Magnetic nanoparticle hyperthermia enhances radiation therapy: A study in mouse models of human prostate cancer.

Authors:  Anilchandra Attaluri; Sri Kamal Kandala; Michele Wabler; Haoming Zhou; Christine Cornejo; Michael Armour; Mohammad Hedayati; Yonggang Zhang; Theodore L DeWeese; Cila Herman; Robert Ivkov
Journal:  Int J Hyperthermia       Date:  2015-03-26       Impact factor: 3.914

Review 2.  Magnetic hyperthermia therapy for the treatment of glioblastoma: a review of the therapy's history, efficacy and application in humans.

Authors:  Keon Mahmoudi; Alexandros Bouras; Dominique Bozec; Robert Ivkov; Constantinos Hadjipanayis
Journal:  Int J Hyperthermia       Date:  2018-02-06       Impact factor: 3.914

3.  Magnetomotive Optical Coherence Elastography for Magnetic Hyperthermia Dosimetry Based on Dynamic Tissue Biomechanics.

Authors:  Pin-Chieh Huang; Paritosh Pande; Adeel Ahmad; Marina Marjanovic; Darold R Spillman; Boris Odintsov; Stephen A Boppart
Journal:  IEEE J Sel Top Quantum Electron       Date:  2015-12-17       Impact factor: 4.544

4.  CaCO₃/CaIP₆ composite nanoparticles effectively deliver AKT1 small interfering RNA to inhibit human breast cancer growth.

Authors:  Hongyan Zhou; Jinhuan Wei; Qiangsheng Dai; Liping Wang; Junhang Luo; Tuckyun Cheang; Shenming Wang
Journal:  Int J Nanomedicine       Date:  2015-07-01

5.  Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application.

Authors:  Hui Ye; Jiansong Tong; Jiangyi Liu; Wenman Lin; Chengshou Zhang; Kai Chen; Jie Zhao; Wenjing Zhu
Journal:  Oncotarget       Date:  2016-07-12

6.  Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.

Authors:  Ethel J Ngen; Ying Chen; Babak Behnam Azad; Srikanth Boinapally; Desmond Jacob; Ala Lisok; Chentian Shen; Mir S Hossain; Jiefu Jin; Zaver M Bhujwalla; Martin G Pomper; Sangeeta R Banerjee
Journal:  Nanotheranostics       Date:  2021-01-19

7.  Enhanced antitumor efficacy of biocompatible magnetosomes for the magnetic hyperthermia treatment of glioblastoma.

Authors:  Raphaël Le Fèvre; Mickaël Durand-Dubief; Imène Chebbi; Chalani Mandawala; France Lagroix; Jean-Pierre Valet; Ahmed Idbaih; Clovis Adam; Jean-Yves Delattre; Charlotte Schmitt; Caroline Maake; François Guyot; Edouard Alphandéry
Journal:  Theranostics       Date:  2017-10-13       Impact factor: 11.556

8.  Enhancing the abscopal effect of radiation and immune checkpoint inhibitor therapies with magnetic nanoparticle hyperthermia in a model of metastatic breast cancer.

Authors:  Arlene L Oei; Preethi Korangath; Kathleen Mulka; Mikko Helenius; Jonathan B Coulter; Jacqueline Stewart; Esteban Velarde; Johannes Crezee; Brian Simons; Lukas J A Stalpers; H Petra Kok; Kathleen Gabrielson; Nicolaas A P Franken; Robert Ivkov
Journal:  Int J Hyperthermia       Date:  2019-11       Impact factor: 3.914

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.